Objective： To provide information about the effectiveness and safety of Ginkgo Leaf Extract and Dipyridamole Injection （GD） as one adjuvant therapy for treating angina pectoris （AP） and to evaluate the relevant r...Objective： To provide information about the effectiveness and safety of Ginkgo Leaf Extract and Dipyridamole Injection （GD） as one adjuvant therapy for treating angina pectoris （AP） and to evaluate the relevant randomized controlled trials （RCTs） with meta-analysis. Methods： RCTs concerning AP treated by GD were searched in China Biology Medicine Disc （SinoMed）, PubMed, the China National Knowledge Infrastructure Database （CNKI）, the Chinese Scientific Journals Database （VIP）, Wanfang Database, Embase, and the Cochrane Library, from inception to February, 2017. The Cochrane Risk Assessment Tool was adopted to assess the methodological quality of the RCTs. The Review Manager 5.3 software was utilized to conduct the meta-analysis. Results： A total of 41 RCTs involving 4,462 patients were included in the meta-analysis. The results indicated that the combined use of GD and Western medicine （WM） against AP was associated with a higher total effective rate [risk ratio （RR）=1.25, 95% confidence interval （CI）： 1.21-1.29, P〈0.01], total effective rate of electrocardiogram （RR=1.29, 95% CI： 1.21-1.36, P〈0.01）. Additional, GD combined with WM could decrease the level of plasma viscosity [mean difference （MD）=-0.56, 95% CI： -0,81 to -0.30, P〈0.01], flbrinogen [MD=-1.02, 95% CI： -1.50 to -0.54, P〈0.01], whole blood low shear viscosity [MD=-2.27, 95% CI： -3.04 to -1.49, P〈0.01], and whole blood high shear viscosity （MD=-0.90, 95% CI： 1.37 to -0.44, P〈0.01）. Conclusions： Comparing with receiving WM only, the combine use of GD and WM was associated with a better curative effect for patients with AP. Nevertheless, limited by the methodological quality of included RCTs more large-sample, multi-center RCTs were needed to confirm our findings and provide further evidence for the clinical utility of GD.展开更多
目的研究银杏达莫注射液对急性脑梗死患者血清基质金属蛋白酶9(MMP-9)、血管内皮功能及预后的影响。方法回顾性分析2012年2月至2014年2月重庆市北部新区第一人民医院接诊的80例急性脑梗死患者的临床资料,依据治疗方法不同分为对照组和...目的研究银杏达莫注射液对急性脑梗死患者血清基质金属蛋白酶9(MMP-9)、血管内皮功能及预后的影响。方法回顾性分析2012年2月至2014年2月重庆市北部新区第一人民医院接诊的80例急性脑梗死患者的临床资料,依据治疗方法不同分为对照组和观察组,各40例。对照组静脉滴注25 m L复方丹参注射液与250 m L 5%的葡萄糖溶液的混合液,每日1次,15 d为1个疗程;观察组静脉滴注15 m L银杏达莫注射液与250 m L 5%的葡萄糖溶液的混合液,每日1次,15 d为1个疗程。比较两组患者疗效。分析两组患者治疗前后的MMP-9、一氧化氮(NO)以及人内皮素1(ET-1)水平,观察两组患者的不良反应发生情况。结果观察组总有效率高于对照组[92.5%(37/40)比70.0%(28/40)],差异有统计学意义(P<0.05)。治疗后,观察组MMP-9水平低于对照组[(3.8±1.9)μg/L比(5.1±1.8)μg/L],差异有统计学意义(P<0.01);观察组NO高于对照组[(64±7)μmol/L比(55±7)μmol/L],ET-1低于对照组[(63±11)ng/L比(76±12)ng/L],差异有统计学意义(P<0.01)。结论银杏达莫注射液可以有效治疗急性脑梗死患者,不良反应少,且有助于降低急性脑梗死患者的MMP-9水平以及改善急性脑梗死患者的血管内皮功能。展开更多
基金Supported by the National Natural Science Foundation of China(No.81473547 and No.81673829)
文摘Objective： To provide information about the effectiveness and safety of Ginkgo Leaf Extract and Dipyridamole Injection （GD） as one adjuvant therapy for treating angina pectoris （AP） and to evaluate the relevant randomized controlled trials （RCTs） with meta-analysis. Methods： RCTs concerning AP treated by GD were searched in China Biology Medicine Disc （SinoMed）, PubMed, the China National Knowledge Infrastructure Database （CNKI）, the Chinese Scientific Journals Database （VIP）, Wanfang Database, Embase, and the Cochrane Library, from inception to February, 2017. The Cochrane Risk Assessment Tool was adopted to assess the methodological quality of the RCTs. The Review Manager 5.3 software was utilized to conduct the meta-analysis. Results： A total of 41 RCTs involving 4,462 patients were included in the meta-analysis. The results indicated that the combined use of GD and Western medicine （WM） against AP was associated with a higher total effective rate [risk ratio （RR）=1.25, 95% confidence interval （CI）： 1.21-1.29, P〈0.01], total effective rate of electrocardiogram （RR=1.29, 95% CI： 1.21-1.36, P〈0.01）. Additional, GD combined with WM could decrease the level of plasma viscosity [mean difference （MD）=-0.56, 95% CI： -0,81 to -0.30, P〈0.01], flbrinogen [MD=-1.02, 95% CI： -1.50 to -0.54, P〈0.01], whole blood low shear viscosity [MD=-2.27, 95% CI： -3.04 to -1.49, P〈0.01], and whole blood high shear viscosity （MD=-0.90, 95% CI： 1.37 to -0.44, P〈0.01）. Conclusions： Comparing with receiving WM only, the combine use of GD and WM was associated with a better curative effect for patients with AP. Nevertheless, limited by the methodological quality of included RCTs more large-sample, multi-center RCTs were needed to confirm our findings and provide further evidence for the clinical utility of GD.
文摘目的研究银杏达莫注射液对急性脑梗死患者血清基质金属蛋白酶9(MMP-9)、血管内皮功能及预后的影响。方法回顾性分析2012年2月至2014年2月重庆市北部新区第一人民医院接诊的80例急性脑梗死患者的临床资料,依据治疗方法不同分为对照组和观察组,各40例。对照组静脉滴注25 m L复方丹参注射液与250 m L 5%的葡萄糖溶液的混合液,每日1次,15 d为1个疗程;观察组静脉滴注15 m L银杏达莫注射液与250 m L 5%的葡萄糖溶液的混合液,每日1次,15 d为1个疗程。比较两组患者疗效。分析两组患者治疗前后的MMP-9、一氧化氮(NO)以及人内皮素1(ET-1)水平,观察两组患者的不良反应发生情况。结果观察组总有效率高于对照组[92.5%(37/40)比70.0%(28/40)],差异有统计学意义(P<0.05)。治疗后,观察组MMP-9水平低于对照组[(3.8±1.9)μg/L比(5.1±1.8)μg/L],差异有统计学意义(P<0.01);观察组NO高于对照组[(64±7)μmol/L比(55±7)μmol/L],ET-1低于对照组[(63±11)ng/L比(76±12)ng/L],差异有统计学意义(P<0.01)。结论银杏达莫注射液可以有效治疗急性脑梗死患者,不良反应少,且有助于降低急性脑梗死患者的MMP-9水平以及改善急性脑梗死患者的血管内皮功能。
